Impel NeuroPharma Announces U.S. Food & Drug Administration Acceptance Of New Drug Application For INP104 For The Acute Treatment Of Migraine
Share this article Share this article SEATTLE, Jan. 20, 2021 /PRNewswire/ -- Impel NeuroPharma, a late-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the companys 5O5(b)(2) New Drug Application (NDA) for INP104 for the acute treatment of migraine headaches with or without aura in adults. INP104 is dihydroergotamine mesylate (DHE) delivered directly into the vascular-rich upper nasal space using Impels proprietary Precis...
Acute Treatment Of Migraine Accepts Trade Name Spending Approval Lead Candidate Proprietary Precision Olfactory Delivery Only Delivery System
Source: prnewswire.com